For research use only
| Cat No. | ABC-TC252S |
| Product Type | Human Leukemia Cell Lines |
| Cell Type | Lymphocyte-like |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Acute Lymphoblastic Leukemia |
| Product Code | Nalm-6; NALM 6; Nalm 6; NALM6; Nalm6; NALM-6-M1 |
NALM-6 cells are B-ALL lymphoblasts with t(5;12) translocation, expressing B-cell markers and forming systemic metastases in immunocompromised mice.
The nalm6 cells are a human B-cell precursor leukemia cell line established from the peripheral blood of a 19-year-old man with acute lymphoblastic leukemia (ALL) in relapse in 1976. NALM-6 cells grow as small, round cells in suspension and are characterized by a B-cell precursor leukemia phenotype. The cells express B-lineage-associated markers including CD10 and CD19, together with cytoplasmic CD79a and cytoplasmic IgM, while surface immunoglobulin expression is absent. Cytogenetic characterization of NALM-6 has identified a near-diploid karyotype and a t(5;12)(q33.2;p13.2) rearrangement. These characteristics support the use of nalm6 cells as an established in vitro model for studying B-cell precursor leukemia biology, cellular phenotypes, and responses to experimental treatments.
| Product Code | Nalm-6; NALM 6; Nalm 6; NALM6; Nalm6; NALM-6-M1 |
| Species | Human |
| Cat.No | ABC-TC252S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte-like |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Acute Lymphoblastic Leukemia |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
NALM-6 cells can be used for research on B-cell precursor acute lymphoblastic leukemia, including studies of leukemia cell proliferation, B-lineage-associated surface markers, therapeutic response, and mechanisms of treatment resistance. Their CD10-positive and CD19-positive phenotype makes NALM-6 suitable for flow cytometric characterization and studies of B-cell leukemia-associated antigens. NALM-6 has also been used to establish cytarabine-resistant derivatives for investigating changes in drug sensitivity, cell-cycle characteristics, and molecular mechanisms associated with chemotherapy resistance. In addition, NALM-6 cells have been used in immunodeficient mouse models to study leukemia engraftment and the distribution of leukemic cells in tissues including bone marrow and liver.
The nalm6 cells support research focused on B-cell precursor acute lymphoblastic leukemia, leukemia cell biology, B-lineage-associated surface markers, therapeutic response, and chemotherapy resistance. Their CD10-positive and CD19-positive phenotype provides a defined model for investigating B-lineage leukemia cells using flow cytometry and other phenotypic approaches. NALM-6 has also been used to investigate acquired resistance to cytarabine and other therapeutic agents, including the characterization of resistant derivatives and associated changes in drug sensitivity and cellular responses. In vivo studies further support the use of NALM-6 in research on leukemia engraftment, tissue infiltration, and interactions between leukemia cells and the bone marrow microenvironment.
Cell Recovery → Cell Expansion → Phenotypic Characterization → Experimental Treatment or Genetic Manipulation → Cell Viability/Proliferation Analysis → Molecular or Cytogenetic Analysis → Therapeutic Response Assessment
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
NALM-6 cell line were originally isolated from peripheral blood of a patient with acute lymphoblastic leukemia (ALL) in relapse.
The seeding density is 2 × 10^5 cells/mL, it is recommended to keep the cell concentration within the range of 1 × 10^5 to 1 × 10^6 cells/mL for optimal growth.
The utility of Nalm-6 cells extends to studying the efficacy of therapeutic targets and existing drug resistance mechanisms, provides a unique way for researching the genomic landscape of the disease, including genomic instability and DNA repair mechanisms. It can also be helpful for studying the complex nature of acute leukemia.
The doubling time of NALM-6 cell line is around 35 to 40 hours. It could be different due to the batches.
